Erasca (ERAS) Stock: Buy, Sell, or Hold?
ERAS - Erasca, Inc. Common Stock
$14.04
-0.45 (-3.11%)
▼
5d:
-5.58%
30d:
+0.68%
90d:
-26.53%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
19d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 13, 2026 at $14.88 · last confirmed Oct 19, 2026
Strength: 8.3/10
Get Alerted When ERAS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ERAS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ERAS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ERAS is currently trading at $14.04, which is considered oversold relative to its 30-day fair value range of $14.06 to $15.47.
Technical Outlook: Technically, ERAS is showing sideways momentum. Immediate support is located at $13.10, while resistance sits at $16.20. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: ERAS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $24.11 (+66.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ERAS is showing sideways momentum. Immediate support is located at $13.10, while resistance sits at $16.20. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: ERAS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $24.11 (+66.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.06 -
$15.47
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Protect Your Profits
Holding ERAS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 66.4% below Wall St target ($24.11)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$14.06 -
$15.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$13.10
Resistance Level
$16.20
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.25
Wall Street Target
$24.11
(+66.4%)
Share & Embed Analysis
Last updated: October 22, 2026 4:41 PM ET
Data refreshes hourly during market hours. Next update: 5:41 PM
Data refreshes hourly during market hours. Next update: 5:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ERAS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 68 BUY |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 71 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 60 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$153 | 68 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
15 analysts |
$108 | 60 BUY |
Advanced ERAS Option Strategies
Professional options setups generated by AI based on today's ERAS price and gamma walls.
